KRAS and neoplasm: Taken together, these results support a paradigm whereby genomic drivers, such as mutated KRAS, and defects in DNA repair pathways/TMB may have counteracting effects on tumor immunogenicity, where contributions from each process are dictated by additional underlying mechanisms specific to tumor types and their microenvironments.